• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

良性多发性硬化症患者的灰质萎缩。

Grey matter atrophy in patients with benign multiple sclerosis.

机构信息

Neuro Center, Neurology, Kuopio University Hospital, Kuopio, Finland.

Combinostics Ltd, Tampere, Finland.

出版信息

Brain Behav. 2022 Jul;12(7):e2679. doi: 10.1002/brb3.2679. Epub 2022 Jun 28.

DOI:10.1002/brb3.2679
PMID:35765699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9304852/
Abstract

BACKGROUND

Brain atrophy appears during the progression of multiple sclerosis (MS) and is associated with the disability caused by the disease.

METHODS

We investigated global and regional grey matter (GM) and white matter (WM) volumes, WM lesion load, and corpus callosum index (CCI), in benign relapsing-remitting MS (BRRMS, n = 35) with and without any treatment and compared those to aggressive relapsing-remitting MS (ARRMS, n = 46). Structures were analyzed by using an automated MRI quantification tool (cNeuro®).

RESULTS

The total brain and cerebral WM volumes were larger in BRRMS than in ARRMS (p = .014, p = .017 respectively). In BRRMS, total brain volumes, regional GM volumes, and CCI were found similar whether or not disease-modifying treatment (DMT) was used. The total (p = .033), as well as subcortical (p = .046) and deep WM (p = .041) lesion load volumes were larger in BRRMS patients without DMT. Cortical GM volumes did not differ between BRRMS and ARRMS, but the volumes of total brain tissue (p = .014) and thalami (p = .003) were larger in patients with BRRMS compared to ARRMS. A positive correlation was found between CCI and whole-brain volume in both BRRMS (r = .73, p < .001) and ARRMS (r = .80, p < .01).

CONCLUSIONS

Thalamic volume is the most prominent measure to differentiate BRRMS and ARRMS. Validation of automated quantification of CCI provides an additional applicable MRI biomarker to detect brain atrophy in MS.

摘要

背景

脑萎缩出现在多发性硬化症（MS）的进展过程中，并与疾病引起的残疾有关。

方法

我们研究了良性复发缓解型多发性硬化症（BRRMS，n=35，有或无任何治疗）和侵袭性复发缓解型多发性硬化症（ARRMS，n=46）的全脑和灰质（GM）、白质（WM）体积、WM 病变负荷和胼胝体指数（CCI），并使用自动 MRI 定量工具（cNeuro®）进行了分析。

结果

BRRMS 的总脑和大脑 WM 体积大于 ARRMS（p=0.014，p=0.017）。在 BRRMS 中，无论是否使用疾病修正治疗（DMT），总脑体积、区域 GM 体积和 CCI 均相似。总病变负荷（p=0.033）、皮质下（p=0.046）和深部 WM（p=0.041）病变负荷在未接受 DMT 的 BRRMS 患者中更大。BRRMS 和 ARRMS 之间的皮质 GM 体积无差异，但 BRRMS 患者的总脑组织（p=0.014）和丘脑（p=0.003）体积大于 ARRMS 患者。在 BRRMS 和 ARRMS 中均发现 CCI 与全脑体积之间存在正相关（BRRMS：r=0.73，p<0.001；ARRMS：r=0.80，p<0.01）。

结论

丘脑体积是区分 BRRMS 和 ARRMS 的最显著指标。CCI 的自动定量验证为检测 MS 中的脑萎缩提供了另一种适用的 MRI 生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2061/9304852/63d70a29acc2/BRB3-12-e2679-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2061/9304852/5efa694b7290/BRB3-12-e2679-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2061/9304852/142695771e7d/BRB3-12-e2679-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2061/9304852/8d5f33c04087/BRB3-12-e2679-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2061/9304852/d67557aaff05/BRB3-12-e2679-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2061/9304852/63d70a29acc2/BRB3-12-e2679-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2061/9304852/5efa694b7290/BRB3-12-e2679-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2061/9304852/142695771e7d/BRB3-12-e2679-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2061/9304852/8d5f33c04087/BRB3-12-e2679-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2061/9304852/d67557aaff05/BRB3-12-e2679-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2061/9304852/63d70a29acc2/BRB3-12-e2679-g003.jpg

相似文献

1
Grey matter atrophy in patients with benign multiple sclerosis.良性多发性硬化症患者的灰质萎缩。
Brain Behav. 2022 Jul;12(7):e2679. doi: 10.1002/brb3.2679. Epub 2022 Jun 28.
2
The impact of deep grey matter volume on cognition in multiple sclerosis.深部灰质体积对多发性硬化症认知功能的影响。
Mult Scler Relat Disord. 2020 Oct;45:102351. doi: 10.1016/j.msard.2020.102351. Epub 2020 Jul 2.
3
Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.血清 GFAP 和 NfL 在良性复发性缓解型多发性硬化症中的水平。
Mult Scler Relat Disord. 2021 Nov;56:103280. doi: 10.1016/j.msard.2021.103280. Epub 2021 Sep 28.
4
Enlarged choroid plexus in multiple sclerosis is associated with increased lesion load and atrophy in white matter but not gray matter atrophy.多发性硬化症患者的脉络丛增大与白质病变负荷和萎缩增加有关，但与灰质萎缩无关。
Mult Scler Relat Disord. 2024 Feb;82:105424. doi: 10.1016/j.msard.2024.105424. Epub 2024 Jan 2.
5
Correlation between the corpus callosum index and brain atrophy, lesion load, and cognitive dysfunction in multiple sclerosis.胼胝体指数与多发性硬化症脑萎缩、病灶负荷和认知功能障碍的相关性。
Mult Scler Relat Disord. 2018 Feb;20:154-158. doi: 10.1016/j.msard.2018.01.015. Epub 2018 Jan 31.
6
Enlarged choroid plexus related to iron rim lesions and deep gray matter atrophy in relapsing-remitting multiple sclerosis.复发缓解型多发性硬化症中与铁环病变和深部灰质萎缩相关的扩大脉络丛。
Mult Scler Relat Disord. 2023 Jul;75:104740. doi: 10.1016/j.msard.2023.104740. Epub 2023 Apr 29.
7
Characterization of gray-matter multiple sclerosis lesions using double inversion recovery, diffusion, contrast-enhanced, and volumetric MRI.采用双反转恢复、弥散、对比增强和容积 MRI 对灰质多发性硬化病变进行特征描述。
Mult Scler Relat Disord. 2019 Jun;31:74-81. doi: 10.1016/j.msard.2019.03.021. Epub 2019 Mar 29.
8
Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2 Lesion Load : A 3-Tesla Magnetic Resonance Imaging Study.复发缓解型多发性硬化症的皮质和皮质下形态计量学及铁变化及其与脑白质 T2 病变负荷的关系：一项 3T 磁共振成像研究。
Clin Neuroradiol. 2019 Mar;29(1):51-64. doi: 10.1007/s00062-017-0654-0. Epub 2018 Jan 3.
9
Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy.早期多发性硬化症中的认知障碍：白质病变、深部灰质萎缩和皮质萎缩的贡献。
J Neurol. 2020 Aug;267(8):2307-2318. doi: 10.1007/s00415-020-09841-0. Epub 2020 Apr 23.
10
The Impact of Intracortical Lesions on Volumes of Subcortical Structures in Multiple Sclerosis.皮质内病变对多发性硬化症皮质下结构体积的影响。
AJNR Am J Neuroradiol. 2020 May;41(5):804-808. doi: 10.3174/ajnr.A6513. Epub 2020 May 7.

引用本文的文献

1
Neuroimaging phenotype characterization of early aggressive and late severe multiple sclerosis: a case-control study.早期侵袭性和晚期重症多发性硬化的神经影像学表型特征：一项病例对照研究。
Brain Commun. 2025 Jun 24;7(4):fcaf254. doi: 10.1093/braincomms/fcaf254. eCollection 2025.
2
AI-driven MRI analysis reveals brain atrophy patterns in benign relapsing-remitting multiple sclerosis.人工智能驱动的磁共振成像分析揭示了良性复发缓解型多发性硬化症中的脑萎缩模式。
Front Neurol. 2025 May 9;16:1570566. doi: 10.3389/fneur.2025.1570566. eCollection 2025.
3
Can International Classification of Functioning, Disability and Health (ICF) Be Used for Prediction of Work Capacity and Employment Status in Multiple Sclerosis?

本文引用的文献

1
A novel CT-based automated analysis method provides comparable results with MRI in measuring brain atrophy and white matter lesions.一种新的基于 CT 的自动分析方法在测量脑萎缩和白质病变方面提供了与 MRI 可比的结果。
Neuroradiology. 2021 Dec;63(12):2035-2046. doi: 10.1007/s00234-021-02761-4. Epub 2021 Aug 14.
2
Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis.无全脑萎缩的丘脑萎缩与多发性硬化症患者两年无疾病进展相关。
Front Neurol. 2019 May 3;10:459. doi: 10.3389/fneur.2019.00459. eCollection 2019.
3
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
国际功能、残疾和健康分类（ICF）能否用于预测多发性硬化症患者的工作能力和就业状况？
J Clin Med. 2024 Jul 18;13(14):4195. doi: 10.3390/jcm13144195.
4
Automated magnetic resonance imaging quantification of cerebral parenchymal and ventricular volume following subarachnoid hemorrhage: associations with cognition.蛛网膜下腔出血后脑实质和脑室容积的自动磁共振成像定量：与认知的关系。
Brain Imaging Behav. 2024 Jan 31;18(2):421-429. doi: 10.1007/s11682-024-00855-0.
尽管在那他珠单抗治疗期间临床和病变稳定，但多发性硬化症仍存在灰质萎缩。
PLoS One. 2018 Dec 21;13(12):e0209326. doi: 10.1371/journal.pone.0209326. eCollection 2018.
4
Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.芬戈莫德对多发性硬化症患者脑灰质、丘脑和白质的影响。
Neurology. 2018 Apr 10;90(15):e1324-e1332. doi: 10.1212/WNL.0000000000005292. Epub 2018 Mar 14.
5
Correlation between the corpus callosum index and brain atrophy, lesion load, and cognitive dysfunction in multiple sclerosis.胼胝体指数与多发性硬化症脑萎缩、病灶负荷和认知功能障碍的相关性。
Mult Scler Relat Disord. 2018 Feb;20:154-158. doi: 10.1016/j.msard.2018.01.015. Epub 2018 Jan 31.
6
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.ECTRIMS/EAN 多发性硬化症药物治疗指南
Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.
7
Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease.多发性硬化症中的丘脑萎缩：疾病过程中神经退行性变的磁共振成像标志物。
Ann Neurol. 2018 Feb;83(2):223-234. doi: 10.1002/ana.25150. Epub 2018 Feb 9.
8
A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.一项为期两年的研究使用大脑灰质体积来评估多发性硬化症中 fingolimod 治疗的反应。
J Neurol Sci. 2017 Dec 15;383:221-229. doi: 10.1016/j.jns.2017.10.019. Epub 2017 Oct 16.
9
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.阿仑单抗治疗复发型多发性硬化症（CARE-MS II）5年随访：疗效与安全性结果
Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.
10
Normative morphometric data for cerebral cortical areas over the lifetime of the adult human brain.成人大脑一生中大脑皮质区域的规范性形态测量数据。
Neuroimage. 2017 Aug 1;156:315-339. doi: 10.1016/j.neuroimage.2017.05.019. Epub 2017 May 13.